12 May 2016 15:14
Hikma Pharmaceuticals PLC
Voting Results of 2016 Annual General Meeting
LONDON, 12 May 2016 - Hikma Pharmaceuticals PLC (the "Company") announces its Annual General Meeting ("AGM"), held at The Westbury, Bond Street, Mayfair, London W1S 2YF on 12 May 2016 commenced at 11:00 am today. All resolutions were duly passed by shareholders by way of a poll. Resolutions 1 to 16 were passed as ordinary resolutions and Resolutions 17 to 19 were passed as special resolutions.
As previously announced, Mr. Breffni Byrne retired from the Board at the close of the AGM.
Copies of the resolutions dealing with special business passed at the AGM have been submitted to the UK Listing Authority for publication through the Listing Authority's Document Viewing Facility.
The total number of votes cast on the poll for each resolution (the full text of the resolutions is detailed in the notice of the AGM dated 7 April 2016). is set out below. The number of Ordinary Shares in issue on 12 May 2016 was 239,385,501.
| Resolution | Votes For | % | Votes Against | % | Votes Withheld |
1 | To receive the 2015 report and accounts | 201,043,426 | 99.83% | 347,462 | 0.17% | 197,375 |
2 | To approve a final dividend of 21 cents per share | 201,588,263 | 100.00% | 0 | 0.00% | 0 |
3 | Appoint PricewaterhouseCoopers LLP as auditors | 198,964,787 | 98.70% | 2,623,476 | 1.30% | 0 |
4 | Authorise the Audit Committee to set the remuneration of the auditors | 194,789,399 | 96.63% | 6,798,864 | 3.37% | 0 |
5 | Appoint Jochen Gann | 199,061,688 | 98.75% | 2,526,551 | 1.25% | 0 |
6 | Appoint John Castellani | 200,675,819 | 99.55% | 912,421 | 0.45% | 0 |
7 | Reappointment of Said Darwazah | 196,614,743 | 97.69% | 4,641,117 | 2.31% | 332,378 |
8 | Reappointment of Mazen Darwazah | 197,410,765 | 97.93% | 4,177,474 | 2.07% | 0 |
9 | Reappointment of Robert Pickering | 199,988,353 | 99.21% | 1,599,886 | 0.79% | 0 |
10 | Reappointment of Ali Al Husry | 199,090,927 | 98.76% | 2,497,312 | 1.24% | 0 |
11 | Reappointment of Michael Ashton | 196,521,848 | 98.45% | 3,095,916 | 1.55% | 1,970,475 |
12 | Reappointment of Ronald Goode | 198,210,008 | 99.05% | 1,901,133 | 0.95% | 1,477,098 |
13 | Reappointment of Patrick Butler | 200,562,012 | 99.49% | 1,026,227 | 0.51% | 0 |
14 | Reappointment of Dr Pamela Kirby | 199,880,568 | 99.15% | 1,707,671 | 0.85% | 0 |
15 | Approve the 2015 remuneration implementation | 173,423,087 | 88.97% | 21,510,812 | 11.03% | 6,654,338 |
16 | Authorise the directors to allot shares | 176,261,935 | 87.65% | 24,841,433 | 12.35% | 484,894 |
17 | Disapply pre-emption rights | 179,904,929 | 90.65% | 18,558,726 | 9.35% | 3,124,607 |
18 | Authorise the company to buy back shares | 200,673,199 | 99.55% | 915,063 | 0.45% | 0 |
19 | Authorise the company to call general meetings on 14 days' notice | 185,097,715 | 91.88% | 16,365,074 | 8.12% | 125,473 |
Declaration of final dividend
The dividend of 21 cents per share will be paid on 19 May 2016 to shareholders on the register on 8 April 2016. Shareholders who are not resident in Jordan have been given the option of receiving their dividend in Pounds Sterling. The exchange rate in respect of this dividend will be $1.4510 to £1. The exchange rate for Jordanian Dinar is fixed to the US Dollar at 1JD to $1.4104.
- ENDS -
Enquiries:
Hikma Pharmaceuticals PLC | |
Peter Speirs Company Secretary
| +44 20 7399 2670 |
Susan Ringdal VP for Investor Relations and Strategy
| +44 20 7399 2670
|
About Hikma
Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based primarily in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe. In 2015, Hikma achieved revenues of $1,440 million and profit attributable to shareholders of $252 million.
Hikma Pharmaceuticals (HIK)